Kala Pharmaceuticals – CRL for KPI-121 0.25% poses a Setback for the Company
Kala Pharmaceuticals (NASDAQ: KALA) received a Complete Response Letter (CRL) from the FDA, asking for efficacy data from an additional trial, in response to its NDA for KPI-121 0.25%, its lead candidate for the treatment of dry eye disease. The company had filed a New...